Using 18F-PSMA PET/CT imaging for detecting prostate-specific tumors
Official title: Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
Run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · NCT05761366 · Data updated 2026-11-12
This study is testing a new type of imaging to see if it can better find prostate-specific tumors in patients with prostate cancer and other related cancers.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Locations | 1 site (Beijing, Chaoyang) |
| Status | Recruiting |
| Started | October 13, 2022 |
| Main results expected | October 13, 2025 |
| Study ends | October 13, 2025 |
| Registry record updated | December 27, 2024 |
| Trial ID | NCT05761366 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with suspected or diagnosed PSMA positive-expressing tumors.
✕Probably not a fit
Patients with serious underlying health conditions or those who have recently participated in other experimental treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of Al18F-PSMA-BCH PET/CT imaging in detecting tumors that express prostate-specific membrane antigen (PSMA). It includes patients with various types of malignancies known to express PSMA, such as prostate cancer and several other carcinomas. The study aims to assess how well this imaging technique can identify these tumors, potentially improving diagnosis and treatment planning.
Why it matters
Potential benefit: If successful, this imaging technique could enhance the accuracy of tumor detection in patients with PSMA positive tumors, leading to better treatment outcomes.
How similar studies have gone: Other studies have shown promise in using PSMA-targeted imaging for tumor detection, indicating a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with suspected or clearly diagnosed PSMA positive-expressing tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc. 2. Age is 18 or older; No gender limitation. 3. Signed the informed consent. 4. Willing and able to cooperate with all projects in this study. Exclusion Criteria: 1. Patients with serious neurological diseases,or gastrointestinal tract disease, cardiovascular disease, liver disease, kidney disease, blood system disease, endocrine system disease, respiratory system disease, immune deficiency disease, etc 2. Claustrophobia. 3. Pregnant or lactation women. 4. Received experimental drug or device within 1 month.
Where it's running
-
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Chaoyang, China Recruiting
Study contacts
- Principal investigator: Rong Zheng, MD — National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and PUMC
- Study coordinator: Xin Cheng, MD
- Email: cxpumc@foxmail.com
- Phone: 15120002998
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sedation Methods in PTBD: How Two Regimens Compare for Quality and Recovery
This study tests two sedation plans (propofol with remifentanil vs propofol with ketamine) to see which helps patients recover faster after PTBD while staying comfortable and safe.
-
Chest wall reconstruction using twisted stainless steel wires versus PMMA bone cement
This project will test whether twisted stainless steel wires or PMMA bone cement gives better outcomes for adults needing chest wall reconstruction after tumor- or infection-related resections.
-
Do repeated hyperbaric oxygen sessions increase DNA damage after radiotherapy?
This tests whether repeated hyperbaric oxygen therapy sessions cause more DNA damage in adults who are receiving HBOT after prior radiotherapy or for related complications.
-
Capmatinib treatment for adults with cancers having MET gene changes
This study is testing if capmatinib, a drug for lung cancer, can help adults with different types of cancers that have changes in the MET gene.
-
Informatics-assisted detection of immune-related side effects to improve biorepository enrollment
This project tests whether an automated system that reads electronic health records can help identify cancer patients on immunotherapy who are having immune-related side effects so they can be enrolled in a biorepository.
-
Imaging method for digestive system cancer using targeted PET scans
This study is testing a new type of PET scan to see if it can better help doctors find and diagnose cancers in the digestive system.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.